ELIDEL® cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis
Québec is the first province to list OKEDI on the public drug reimbursement formulary for the treatment of schizophrenia
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of OKEDI® for the treatment of schizophrenia
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
SAGA Metals Reports Assays from R-0058 to R-0060 with Intercepts Including 43.86% Fe2O3, 6.10% TiO2, 0.317% V2O5 from 2026 Drilling at Radar Critical Minerals Project in Labrador and Adds to Its Advisory Board
